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Purpose
The purpose of this study was to examine the motiva-
tional, attitudinal, and behavioral predictors of interest in 
genetic testing (GT) in those with and without awareness 
of their risk for type 2 diabetes (T2DM).
Methods
A convenience sample of adults visiting emergency 
departments, libraries, or an online research registry was 
surveyed. Responses from adults without diabetes who 
reported 1 or more risk factors for T2DM (eg, family his-
tory, body mass index > 25) were included in the analy-
ses (n = 265).
Results
Participants were 37 ± 11 years old, white (54%), and 
female (69%), with some college education (53%) and an 
annual income below $25 000 (44%). Approximately 
half (52%) expressed interest in GT for T2DM. 
Individuals were stratified by perceived risk for T2DM 
(risk aware or risk unaware). Among the risk aware, 
younger age (P < .04) predicted greater interest in GT. 
Among the risk unaware, family history of T2DM (P < 
.008) and preference to know genetic risk (P < .0002) 
predicted interest in GT. Both groups identified the need 
for low-cost GT.
Conclusions
GT is an increasingly available and accurate tool to pre-
dict T2DM risk for patients. In this sample, GT was a 
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salient tool for those with and without awareness of their 
T2DM risk. Financial accessibility is critical to use of 
this tool for both groups.
S
ixty-eight percent of Americans are over-
weight or obese, with approximately 26 mil-
lion estimated to have diagnosed or 
undiagnosed type 2 diabetes (T2DM). An 
additional estimated 79 million adults older 
than 30 years have prediabetes, placing them at signifi-
cant risk of developing T2DM. By 2050, an estimated 1 
in 3 people will be diagnosed with T2DM.1 In 2012 alone, 
T2DM cost $245 billion, accounting for 1 in 5 health care 
dollars.2 At the same time, there is strong evidence that 
behavioral interventions can effectively delay or prevent 
the onset of T2DM.3 Individuals with prediabetes repre-
sent the next wave of patients to be diagnosed with 
T2DM. Those with low perceived risk of T2DM are the 
least likely to engage in diabetes prevention strategies or 
formal programs and therefore represent the highest like-
lihood of progressing to diagnosis of T2DM.
Genetic testing represents a rapidly growing and 
increasingly accessible form of information about T2DM 
risk. Through the recent successes of genomewide asso-
ciation studies, approximately 60 single-nucleotide poly-
morphisms have been robustly associated with T2DM4-16 
and related traits.17-21 More single-nucleotide polymor-
phisms will be identified in the coming years. Genetic 
factors alone can significantly predict incident T2DM 
over the life course22-33 and are independent of family 
history.34 The recent advances in genetic technology 
have decreased costs of genotyping and whole genome 
sequencing exponentially,35 where the expected cost will 
be approximately $1000 in the next few years.36-38 
Lowered costs and recent discoveries are already leading 
to increasingly cost-effective39,40 clinical applications. 
Additionally, there is an increasing demand to utilize 
genomics by providers and patients.41
Knowledge of personal genetic risk, coupled with the 
means to behaviorally reduce risk (ie, the availability of 
diabetes prevention programs), has the potential to syn-
ergistically motivate individuals to engage in diabetes 
prevention. To date, few studies have examined the util-
ity of genetic testing as a tool to assist individuals in 
precisely estimating risk of disease onset and motivating 
behavior change to prevent the onset of disease.42 Only 1 
study has evaluated risk perception and T2DM preven-
tion.43 Grant and colleagues classified 108 adults with 
high or low genetic risk and then compared their motiva-
tion to engage in lifestyle changes, as well as their par-
ticipation in a diabetes prevention program, to controls.43 
High-risk participants showed significant increases in 
motivation to make lifestyle changes and participate in 
the diabetes prevention program (P = .01) compared to 
controls, but no significant differences in attendance 
were observed. The genetic counseling session was posi-
tively received, and it improved perceptions of control 
over the onset of T2DM in the high-risk group.44 This 
suggests that genetic risk information may contribute to 
motivating behavior change. However, the sample pre-
dominantly comprised people who already perceived 
themselves to be at high risk for T2DM, and it sheds little 
light on those who underestimate their risk of T2DM 
despite the presence of absolute risk factors. Those who 
underestimate their risk pose the greatest challenge to 
health care systems and providers, as they are the least 
likely to engage in preventive behaviors, potentially 
resulting in greater costs and poorer health outcomes.
Taken together, the epidemic of obesity and metabolic 
disorder that precede the development of T2DM illumi-
nates the need to assist high-risk individuals to identify 
their risk for the development of T2DM and engage in 
diabetes prevention. Genetic testing is emerging as a 
cost-effective tool to assist individuals in precisely esti-
mating this risk in addition to known behavioral and 
environmental factors. To date, little is known about 
motivation, attitudes, and behaviors related to genetic 
testing among those with T2DM risk factors. The pur-
pose of the current study was to examine the motiva-
tional, attitudinal, and behavioral predictors of interest in 
genetic testing among those with one or more risk factors 
for T2DM, stratified by perceived risk for T2DM: risk 
aware (RA) or risk unaware (RUA).
Methods
Study Sample
The total study sample was 649 adults who were aged 
18 to 65 years and residents of Indiana. A convenience 
sample of participants from 14 public libraries (n = 342, 
53%) and the emergency room of Wishard Hospital (n = 
62, 10%) and individuals responding online (n = 245, 
37%) through a research registry (INResearch.org) were 
recruited from June to July 2012. These 3 settings were 
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chosen to maximize representation of diverse groups that 
have been underrepresented in prior genetic utilization 
research. INResearch is a registry of more than 900 
research volunteers. The Indianapolis Public Library sys-
tem has 23 sites around the city, offering resources and 
services for learning as well as to promote the social and 
economic interests of its communities. Wishard Hospital 
is the safety-net health system of Indianapolis, with a spe-
cial emphasis on vulnerable populations. The Wishard 
Hospital emergency room and library sites in lower socio-
economic neighborhoods were specifically chosen to 
obtain the broadest representation of demographic, socio-
economic status, and literacy. The study was approved by 
the Indiana University Institutional Review Board.
Questionnaire
Consistent with standard survey development proce-
dures,45 survey questions were developed by one of the 
authors, using extant literature on the assessment of atti-
tudes, beliefs, and behaviors associated with genetic test-
ing in T2DM and other chronic diseases. An initial sample 
of 75 items were created and distributed to 5 experts in the 
fields of psychology, sociology, and anthropology for eval-
uation. Following revisions, items were piloted in a group 
of 10 participants for clarity of wording. Based on feed-
back, items were then edited, resulting in a total of 59 
items. Demographic, personal, and family medical history 
and psychosocial and behavioral factors related to interest 
in genetic testing for T2DM risk prediction were included 
in the final survey instrument. Demographic, perceived 
health, diabetes risk, and medical history questions were 
adapted from standardized questionnaires. Genetics 
knowledge was adapted from existing questionnaires.
To capture the widest variety of attitudinal and behav-
ioral constructs related to genetic testing, psychosocial 
questions were informed Health Belief Model, the 
Theory of Planned Behavior and Reasoned Action, the 
Social Cognitive Theory, the Transactional Model of 
Stress and Coping, and the Precaution Adoption Process 
Model. Questions relating to constructs developed or 
adopted by these behavior change models included per-
ceived health, perceived risk, awareness, knowledge, 
worry, motivation, utility, barriers, trust, and intention. 
The questions were designed to query participants about 
genetics, genetic testing, T2DM, and T2DM risk.
Questions relating to worry about risk of T2DM were 
measured with a 7-point Likert scale. All other questions 
used a 5-point Likert scale. Items (n = 5) assessing 
knowledge of genetics or genetic literacy were scored 
with 1 point given to each question answered correctly 
and summed to create a genetics knowledge total score 
(range = 0-5). A score of 4 or greater indicated high lev-
els of knowledge about genetic testing.
Questionnaires were self-administered through paper 
or web-based versions, available in English or Spanish 
(1.8% of total surveys). The online questionnaire was 
distributed to prospective participants registered at 
Indiana’s volunteer research participant registry. The 
printed version of the questionnaire was handed to eli-
gible participants by trained interviewers at the public 
libraries or the emergency department waiting room of 
Wishard Hospital. After completing the survey, each 
study participant was compensated with a $10 gift card 
and offered educational materials describing diabetes, 
risk factors and symptoms, and the Genetic Information 
Nondiscrimination Act (or GINA bill). All materials 
were available in both English and Spanish.
Statistical Analyses
SAS 9.3 was used for all statistical analyses. A total 
sample of 649 individuals completed the questionnaire. 
Individuals were excluded based on self-reported diabe-
tes (n = 50) and body mass index < 15 kg/m2 (n = 1). Of 
these, only individuals self-reporting the following char-
acteristics were included in the current analyses: self-
reported race as black or white, 1 or more risk factors for 
T2DM (body mass index, family history of T2DM, or 
gestational diabetes), and a response to the item evaluat-
ing perceived risk of developing T2DM as likely (RA) or 
unlikely (RUA). This resulted in a final sample of 265 
participants. RUA individuals were defined as those 
reporting low perceived risk and having at least 1 risk 
factor T2DM (body mass index > 25 kg/m2, family his-
tory, or gestational diabetes; n = 169). RA individuals 
were defined as rating themselves with high perceived 
risk and at least 1 risk factor for T2DM (n = 69). The 
dependent variable was individuals reporting interest in 
genetic testing to predict future risk of developing T2DM 
(yes vs no/not sure). Univariate logistic regression analy-
ses were performed by RA/RUA status. Independent 
variables (n = 47) included demographic variables, moti-
vation, knowledge, or intention to engage in genetic test-
ing for T2DM risk prediction. Variables reaching 
significance at P = .001 or better (Bonferroni correction 
for 46 independent tests) or were psychosocially relevant 
and age, sex, ethnicity, recruitment location were entered 
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into multivariate logistic regression models for RA and 
RUA separately.
Results
For the 265 participants in these analyses, 52% had a 
family history of T2DM; 83% had a body mass index > 25 
kg/m2; 3% reported a history of gestational diabetes; and 
58% reported low perceived risk for developing T2DM. 
Demographic characteristics of the sample by risk estima-
tion group are shown in Table 1, where 64% are RUA and 
36% are RA. A greater proportion of those with RA were 
white (P < .01). A larger proportion of those with RUA 
were male (P = .05). Those with RA were more likely to 
indicate interest in genetic testing (58%) compared to 
those with RUA (45%, P < .04, data not shown).
Multivariate analyses were conducted to identify pre-
dictors of interest in genetic testing for RA and RUA indi-
viduals in separate models in which demographic 
characteristics and significant predictors from the univari-
ate models were entered simultaneously. For RA individu-
als (see Table 2), interest in genetic testing was best 
predicted by younger age (P = .04) and no cost of genetic 
testing to the individual (P = .0001). Sex, ethnicity, or 
increased motivation to engage in genetic testing due to 
accuracy of the test was not associated with interest among 
the RA individuals. Among those with RUA (see Table 3), 
predictors of interest in genetic testing included increased 
motivation by positive family history of T2DM (P = .008), 
preference to know risk before diagnosis (P = .0002), and 
no cost of genetic testing to the individual (P = .0002). 
Age, sex, ethnicity, recruitment location, familiarity with 
Table 1
Characteristics of the Study Population, No. (%)
Risk Unaware (n = 169) Risk Aware (n = 96) P
Age,a y 36.1 ± 10.9 37.2 ± 10.5 .39
Sex, female 117 (69.2) 77 (80.2) .05
Income
< $25 000 66 (39.1) 44 (45.8) .36
$25 000-$50 000 47 (27.8) 27 (28.1)
$50 001-$75 000 19 (11.2) 6 (6.3)
$75 001-$100 000 16 (9.5) 12 (12.5)
 >$100,000 21 (12.4) 7 (7.3)
Health insurance
 Commercial 96 (57.1) 49 (51.0) .52
 Medicaid 26 (15.5) 21 (21.9)
 Medicare 10 (6.0) 4 (4.2)
 Other 36 (21.4) 22 (22.9)
Ethnicity
 Black 80 (47.3) 30 (31.3) .01*
 White 89 (52.7) 66 (68.8)
Education
College or more 85 (50.3) 46 (47.9) .96
Some college 39 (23.1) 22 (22.9)
Completed high school 29 (17.2) 17 (17.7)
Some/less high school 16 (9.5) 11 (11.5)
Marital status
 Cohabitating 13 (7.7) 10 (10.4) .75
 Married 59 (34.9) 32 (33.3)
 Single 97 (57.4) 54 (56.3)
aMean ± SD.
*P < .05.
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someone with diabetes complications, and belief that dia-
betes is preventable were not significantly associated with 
genetic testing interest among the RUA group.
Discussion
In the current study, demographic and psychosocial 
predictors of genetic testing utilization were examined in 
those with T2DM risk unawareness compared to those 
who correctly identified themselves as having elevated 
risk. Differences in the patterns of interest in genetic test-
ing were observed across these 2 groups suggesting that 
use of genetic testing is salient for both groups but the 
usefulness differs by patients’ perceptions of their risk for 
T2DM. For example, data indicated that among those 
with RA, younger participants were more receptive to 
genetic testing, suggesting that older adults may need 
additional information about the utility and relevance of 
genetic testing. This is noteworthy in light of the addi-
tional risk factors for T2DM with increasing age.
Table 2
Multivariate Analyses of Demographic and Psychosocial Associations With Interest in Genetic Testing for Type 2 Diabetes 
Risk Prediction Among Risk Awarea (n = 96)
Odds Ratio (95% Confidence Interval) P
Age (per year) 0.95 (0.90, 1.00) .0452*
Female vs male 0.99 (0.25, 3.90) .9926
Black vs white 0.31 (0.10, 0.97) .1939
Recruitment location 2.53 (0.60, 10.6) .2052
Accuracy of test increases motivation for genetic testing 2.48 (0.79, 7.82) .1215
Would be interested in genetic testing if free of cost 34.2 (5.5, 210.7) .0001*
aAdjusted for age, sex, ethnicity, and recruitment location.
*P < .05.
Table 3
Multivariate Analyses of Demographic and Psychosocial Associations With Interest in Genetic Testing for Type 2 Diabetes 
Risk Prediction Among Risk Unawarea (n = 169)
Odds Ratio (95% Confidence Interval) P
Age 1.01 (0.97, 1.06) .5122
Sex 1.75 (0.65, 4.74) .2701
Black vs white 0.76 (0.30, 1.93) .5615
Recruitment location 0.85 (0.32, 2.27) .7420
Currently motivated to have genetic testing for type 2 diabetes risk due to . . .
Family history of type 2 diabetes 3.95 (1.43, 10.9) .0079
Prefer to know risk before diagnosis 5.58 (2.23, 13.9) .0002*
Know someone with diabetes complications 0.76 (0.28, 2.04) .5869
Would be interested in genetic testing if . . .
Free of cost 24.9 (4.46, 128.0) .0002*
Diabetes is preventable 2.67 (0.49, 14.5) .2537
aAdjusted for age, sex, ethnicity, and recruitment location.
*P < .05.
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In contrast, those with RUA were more likely to be 
interested in genetic testing if they had a family history of 
T2DM and some interest in knowing their risk. Although 
these individuals did not perceive themselves to be at risk 
for T2DM, their awareness of traditional risk factors (eg, 
family history) in conjunction with curiosity about their 
own status increased their likelihood to make use of genetic 
testing as an additional source of information about their 
health. For this crucial group in which risk factors are high 
and prevention steps could be taken to significantly reduce 
risk and prevent disease onset, these findings suggest that 
primary care providers may use traditional risk factor infor-
mation in conjunction with accessible genetic testing to 
demonstrate to patients the relevance that diabetes preven-
tion programs may have on preserving health and reducing 
risk for T2DM. In this group, genetic testing has the poten-
tial to engage the patients’ curiosity about their predisposi-
tion about disease and, in turn, enhance their motivation to 
engage in diabetes prevention.
Another finding from these data is the need for finan-
cially accessible genetic testing. Both groups (RA and 
RUA) indicated greater interest in genetic testing if cost 
to the individual was minimal. As technological innova-
tions lower the cost of testing, health care providers, 
laboratories, and insurers will need to attend to the cost-
benefit ratio of supplementing the cost of genetic testing 
to enhance the accessibility and desirability of testing for 
T2DM genetic risk.
There are 2 primary limitations to the current study. 
Data were collected from a convenience sample of 
research volunteers and those attending an emergency 
department or public library. While this may introduce 
bias, data were intentionally collected across the spec-
trum of sociodemographic characteristics, and, indeed, 
differences in demographic characteristics by recruit-
ment location were observed. This variable was entered 
into multivariate analyses, and it was not a significant 
predictor of genetic testing in either risk group. Second, 
all data, including body mass index and history of 
T2DM, were self-reported and not measured indepen-
dently by the research staff. Body mass index was esti-
mated from self-reported height and weight and should 
be interpreted as approximations to actual values.
Implications for Diabetes Education
As rates of obesity and prediabetes continue to rise, 
there is a need to fully utilize all available tools to iden-
tify risk of T2DM and mitigate that risk through diabetes 
prevention. Those who are RUA are the least likely to 
engage in diabetes prevention. Genetic testing is a new 
tool that will become increasingly available to health care 
providers and patients, and it represents greater accuracy 
of prediction than that of conventional risk factors. The 
current study found that RA and RUA groups both identi-
fied genetic testing as a salient tool for the prediction of 
T2DM, although predictors differed by group. Future use 
of genetic testing to estimate risk of T2DM will depend 
on the perceived utility and financial accessibility of this 
tool by patients. Genetic testing has the potential to add 
to the set of metrics that health care providers can use to 
empower patients with advanced knowledge about their 
health, to identify risk, and to prevent T2DM.
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